Yes, so Biz development / life science investor is being spoken about differently to collaborations.
Collaborations much more likely in the near term with, as you say, validated delivery, although that has been there for a while and the latest results were more to do with dosing toxicity of their drug. Maybe it's still relevant for other drugs..?
The big company changing biz dev / life science investors want the blockbuster drugs, so not likely eyes. Maybe kidneys, def CNS. This is why it will take a while for a deal to come through on that side. Too early stage, for now. Which is why I'm questioning whether someone is really managing the register as you suggest. Or if they are, whether it's a big US firm or maybe just a smaller fund manager or Aust investor group. Volume WAY too small for large US investor, who probably consider 100% of the business too small to invest, let alone 1/2 % volumes that go through our market.
We're all speculating, which can be fun, but I suspect (like the last 15 years I've been in this stock) that more patience will be required. Even though I've been here for a while and made good coin from my 1c av cost there is no way I'm getting rid of any and am more than happy to wait. This has more potential than any other stock I can see / understand - with the added benefit of it being able to really, really help a lot of people. Love it.
PYC Price at posting:
15.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)